在青少年脊椎关节炎的药物治疗
Hemalatha Srinivasalu1,2, Jessica Simpson2, Matthew L Stoll3
1GW University School of Medicine.
Current opinion in rheumatology
|April 19, 2024
概括
新的生物疗法,包括IL-17和IL-23阻塞剂,为青少年脊椎关节炎 (JSpA) 提供了改进的治疗选择,包括与肠炎相关的关节炎 (ERA) 和青少年牛皮关节炎 (JPsA). 这些进展显示出有利的安全性和有效性概况.
科学领域:
- 儿科风湿病学 儿科风湿病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 青少年脊椎关节炎 (JSpA) 包括诸如肠炎相关关节炎 (ERA) 和青少年牛皮关节炎 (JPsA) 这样的亚型.
- 传统的治疗方法有局限性,需要探索新的治疗药物.
- 针对性生物疗法的发展改变了儿科类类风湿性疾病的管理策略.
研究的目的:
- 审查JSpA治疗的最新进展,重点关注ERA和JPsA.
- 总结新批准和新兴的生物疾病修饰抗风湿药物 (bDMARDs) 的疗效和安全性.
- 突出临床试验设计和监管批准对儿科患者群体的挑战.
主要方法:
- 最近的临床试验和观察性研究的文献综述.
- 对生物疗法数据的分析,包括IL-17抑制剂,IL-23抑制剂和Janus激酶抑制剂.
- 基于推断研究和现实世界的证据对监管批准的审查.
主要成果:
- 除了TNF抑制剂之外的生物DMARDs,如IL-17和IL-23抑制剂,在JSpA中表现出有利的安全性.
- 特定的bDMARDs (adalimumab,etanercept,infliximab,seukinumab) 在ERA和JPsA中显示出显著的疗效.
- 美国食品和药物管理局对JPsA的批准包括golimumab,etanercept,atacept和ustekinumab,这些药物通常是基于推断数据的.
结论:
- 新型药物疗法显著扩大了JSpA患者的治疗选择.
- 这些新药的长期安全性概况仍然可以接受.
- 需要进一步研究JSpA管理的现实世界有效性和降级策略.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
161
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
161
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
136
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
136
01:29Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
01:28Drug Therapy
43
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
43
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
116
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
116
01:29Drugs for Treatment of Ulcerative Colitis in IBD
138
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
138